3. (amended) The composition according to Claim 1 comprising a combination of ritonavir and (2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)-amino-3-hydroxy-5-(2S-(1-tetrahydropyrimid-2-onyl)-3-methyl-butanoyl)amino-1,6-diphenylhexane.

4. (amended) The composition according to Claim 1 comprising ritonavir or a combination of ritonavir and another HIV protease inhibiting compound selected from the group consisting of:

(2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)-amino-3-hydroxy-5-(2S-(1-tetrahydropyrimid-2-onyl)-3-methyl-butanoyl)amino-1,6-diphenylhexane;
indinavir;
saquinavir;
5(S)-Boc-amino-4(S)-hydroxy-6-phenyl-2(R)-phenylmethylhexanoyl-(L)-Val-(L)-Phe-morpholin-4-ylamide;
1 -Naphthoxyacetyl-beta-methylthio-Ala-(2S, 3S)- 3-amino-2-hydroxy-4-butanoyl 1,3-thiazolidine-4-t-butylamide;
5-isoquinolinoxyacetyl-beta-methylthio-Ala-(2S,3S)-3-amino-2-hydroxy-4-butanoyl-1,3-thiazolidine-4-t-butylamide;
[1S-[1R-(R-),2S*])-N[1] [3-[[[(1,1 -dimethylethyl)amino]carbonyl](2-methylpropyl)amino]-2-hydroxy-1 -(phenylmethyl)propyl]-2-[(2quinolinylcarbonyl)amino]-butanediamide;



;


HO
O
N
N
OH
HO
OH

;


H2N
O
N
N
NH2
HO
OH

;

nelfinavir;


BocHN
OH
H
N
OH
NHBoc
Ph
O
N
O
O

;


H
N
O
N
H
H
N
OH
N
H
N
O
O
Ph

;



; and

tipranavir;
or a pharmaceutically acceptable salt thereof.

5. (amended) The composition according to Claim 1 wherein said fatty acid is oleic acid.

6. (amended) The composition according to Claim 1 wherein said surfactant is polyoxyl 35 castor oil.

---

10. (amended) The composition of Claim 9 comprising ritonavir or a combination of ritonavir and another HIV protease inhibiting compound selected from the group consisting of:
(2S, 3S, 5S)-2-(2,6Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl]-amino-1,6-diphenylhexane;
indinavir;
saquinavir;

5(S)-Boc-amino-4(S)-hydroxy-6-phenyl-2(R)-phenylmethylhexanoyl-(L)-Val-(L)-Phe-morpholin-4-ylamide;
1 -Naphthoxyacetyl-beta-methylthio-Ala-(2S, 3S)- 3-amino-2-hydroxy-4-butanoyl 1,3-thiazolidine-4-t-butylamide;
5-isoquinolinoxyacetyl-beta-methylthio-Ala-(2S,3S)-3-amino-2-hydroxy-4-butanoyl-1,3-thiazolidine-4-t-butylamide;
[1S-[1R-(R-),2S*])-N^{1} [3-[[[(1,1 -dimethylethyl)amino]carbonyl](2-methylpropyl)amino]-2-

hydroxy-1 -(phenylmethyl)propyl]-2-[(2quinolinylcarbonyl)amino]-butanediamide;



;



;



;

nelfinavir;



;



;

A3
Cont.



; and

tipranavir:

or a pharmaceutically acceptable salt thereof.

11. (amended) The composition of Claim 9 comprising ritonavir or a combination of ritonavir and another HIV protease inhibiting compound selected from the group consisting of: (2S, 3S, 5S)-2-(2,6-dimethylphenoxyacetyl) amino-3-hydroxy-5-(2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl-butanoyl)-amino-1,6-diphenylhexane, indinavir, saquinavir, nelfinavir,



and tipranavir; or a pharmaceutically acceptable salt thereof.

14. (amended) The composition of Claim 1 which comprises:

(a) solubilized ritonavir in the amount of from about 1% to about 30% by weight of the total solution;

(b) a pharmaceutically acceptable organic solvent which comprises (i) oleic acid in the amount of from about 30% to about 75% by weight of the total solution and (2) ethanol in the amount of from about 3% to about 12% by weight of the total solution; and

(c) water in the amount of from about 0.4% to about 3.5% by weight of the total solution; and

(d) polyoxyl 35 castor oil in the amount of from about 0% to about 20% by weight of the total solution.

15. (amended) A pharmaceutical composition comprising:

(a) ritonavir in the amount of about 10% by weight of the total solution,

(b) a pharmaceutically acceptable organic solvent which comprises (1) oleic acid in the amount of from about 70% to about 75% by weight of the total solution; and (2) ethanol in the amount of from about 3% about 12% by weight of the total solution;

(c) water in the amount of from about 0.4% to about 1.5% by weight of the total solution; and

(d) polyoxyl 35 castor oil in the amount of about 6% by weight of the total solution.

17. (amended) The composition of Claim 1 which comprises:

(a) a combination of ritonavir and (2S, 3S, 5S)-2-(2,6-dimethylphenoxyacetyl) amino-3-hydroxy-5-(2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl)-amino-1,6-diphenylhexane in the amount of from about 1% to about 45% by weight of the total solution;

(b) a pharmaceutically acceptable organic solvent which comprises (i) oleic acid in the amount of from about 30% to about 75% by weight of the total solution and (2) propylene glycol in the amount of from about 1% to about 15% by weight of the total solution; and

(c) water in the amount of from about 0.4% to about 3.5% by weight of the total solution.

18. (amended) The composition of Claim 17 which comprises:

(a) a combination of ritonavir and (2S, 3S, 5S)-2-(2,6-dimethylphenoxyacetyl) amino-3-hydroxy-5-(2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl) amino-1,6-diphenylhexane in the amount of from about 1% to about 45% by weight of the total solution,

(b) a pharmaceutically acceptable organic solvent which comprises (1) oleic acid in the amount of from about 70% to about 75% by weight of the total solution; and (2) propylene glycol in the amount of from about 1% about 8% by weight of the total solution;

(c) water in the amount of from about 0.4% to about 1.5% by weight of the total solution; and

(d) polyoxyl 35 castor oil in the amount of from about 2.5% to about 10% by weight of the total solution.

Please add the following new claims:

20. (new) (amended) A pharmaceutical composition comprising:

(a) a combination of solubilized ritonavir in the amount of about 3.9% by weight of the total solution and (2S, 3S, 5S)-2-(2,6-dimethylphenoxyacetyl) amino-3-hydroxy-5-(2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl) amino-1,6-diphenylhexane in the amount of about 15.6% by weight of the total solution,

(b) a pharmaceutically acceptable organic solvent which comprises (1) oleic acid in the amount of about 70% by weight of the total solution; and (2) propylene glycol in the amount of about 7.5% by weight of the total solution;

(c) water in the amount of about 0.5% by weight of the total solution; and

(d) polyoxyl 35 castor oil in the amount of about 2.5% by weight of the total solution.

21. (new) The composition of Claim 20 wherein the solution is encapsulated in a soft elastic gelatin capsule (SEC).